Literature DB >> 11459747

Central benzodiazepine receptors in malformations of cortical development: A quantitative study.

A Hammers1, M J Koepp, M P Richardson, C Labbé, D J Brooks, V J Cunningham, J S Duncan.   

Abstract

We calculated [(11)C]flumazenil volume of distribution ([(11)C]FMZ-V(d)) after correction for partial volume effect in 10 patients with malformations of cortical development (MCDs) and partial seizures, to quantify the GABA(A)-central benzodiazepine receptor complex. Abnormal grey matter and adjacent or overlying cortex were outlined individually and added to an individualized anatomical template for correction for partial volume effect. Nine of 10 patients showed single or multiple increases or decreases in [(11)C]FMZ-V(d) in or around MCDs. Two of three patients with band heterotopia showed multiple increases in the overlying cortex. In three of four patients with subependymal nodular heterotopia, nodules had lower [(11)C]FMZ-V(d) than the overlying cortex, which was normal. Decreases in [(11)C]FMZ-V(d) were found in two of three clefts and one of six adjacent regions in one schizencephalic patient; another had normal [(11)C]FMZ-V(d) in the thickened cortex itself but increases in all adjacent regions. Binding was reduced within focal cortical dysplasia but increased in adjacent cortex. [(11)C]FMZ-V(d) was normal within one patient's polymicrogyric cortex but increased in one of six adjacent volumes of interest. The localization of abnormalities correlated with EEG and clinical data in cortical MCDs. Flumazenil binding was decreased in some MCDs with increased grey matter volume and increased in some adjacent or overlying areas of normal-appearing cortex, suggesting functional abnormalities beyond MRI- detectable structural changes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11459747     DOI: 10.1093/brain/124.8.1555

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  7 in total

1.  Implementation and application of a brain template for multiple volumes of interest.

Authors:  Alexander Hammers; Matthias J Koepp; Samantha L Free; Matthew Brett; Mark P Richardson; Claire Labbé; Vincent J Cunningham; David J Brooks; John Duncan
Journal:  Hum Brain Mapp       Date:  2002-03       Impact factor: 5.038

Review 2.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

Review 3.  Functional neuroimaging in the preoperative evaluation of children with drug-resistant epilepsy.

Authors:  Sandeep Sood; Harry T Chugani
Journal:  Childs Nerv Syst       Date:  2006-06-24       Impact factor: 1.475

4.  Metabolic characteristics of cortical malformations causing epilepsy.

Authors:  S G Mueller; K D Laxer; J A Barakos; N Cashdollar; D L Flenniken; P Vermathen; G B Matson; M W Weiner
Journal:  J Neurol       Date:  2005-04-29       Impact factor: 4.849

5.  Kinetic modelling of [11C]flumazenil using data-driven methods.

Authors:  Isabelle Miederer; Sibylle I Ziegler; Christoph Liedtke; Mary E Spilker; Matthias Miederer; Till Sprenger; Klaus J Wagner; Alexander Drzezga; Henning Boecker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-29       Impact factor: 9.236

Review 6.  Advances in neuroimaging: management of partial epileptic syndromes.

Authors:  Barbara Schäuble; Gregory D Cascino
Journal:  Neurosurg Rev       Date:  2003-08-22       Impact factor: 3.042

7.  Use of a standardized uptake value for parametric in vivo imaging of benzodiazepine receptor distribution on [11C]flumazenil brain PET.

Authors:  Masahito Tsukamoto; Chietsugu Katoh; Tohru Shiga; Tomohito Kaji; Yuji Kuge; Kunihiro Nakada; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-21       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.